References
- Carella A. M., Carlier P., Congiu A. Autologous BMT as adjuvant therapy for high risk Hodgkin's disease in first remission after MOPP-ABVD protocol. Bone Marrow Transplantation 1991; 8: 99–103
- Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Intern. Med 1986; 104: 739–746
- Jagannath S., Dicke K. A., Armitage J. O. High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann. Intern. Med 1986; 104: 163–168
- Carella A. M., Congiu A., Occhini D. Nine years experience with ABMT in 128 patients with Hodgkin's disease of the Italian Cooperative Study Group. Fifth Intern. Symposium: Autologous Bone Marrow Transplantation, KA. Dicke, JO. Armitage. Nebraska University, Omaha 1991; 509–518
- Henry-Amar M., Sommers R. Survival outcome after Hodgkin's disease: A report from the International data base on Hodgkin's disease. Semin. Oncol 1990; 17: 758–768
- Canellos G. P., Anderson J. R., Propert K. J. Chemotherapy of advanced Hodgkin' s disease with MOPP, ABVD, or MOPP alternating with ABVD. New Engl. J. Med 1992; 327: 1478–1484
- Carde P., Bergsagel D. E., Nissen N. I. The treatment of advanced Hodgkin's disease: strategy. Treatment strategy in Hodgkin's disease, Colloque INSERM, R. Somers, M. Henry-Amar, J. H. Meerwaldt, P. Carde. John Libbey, Eurotext LTD., Les Editions INSERM, London, Paris 1990; Vol. 196: 105–108; 196
- Carde P. Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments?. Leukemia and Lymphoma 1995; 15: 31–40, Suppl. 1
- Klimo P. Evolution of the concept of prognostication in therapy of Hodgkin's Lymphoma. Leukemia and Lymphoma 1995; 15: 15–18, Suppl. 1
- Hasenclever D., Schmitz N., Loeffler M. Advanced Hodgkin's disease in first CR or PR: Do parameters present at diagnosis identify a high risk group qualifying for autologous stem cell transplantation?. Proc. ASCO 1994; 13: 1279, (abstr).
- Reece D. E., Connors J. M., Spinelli J. J. Intensive therapy with cyclophosphamide, carmustine, etoposide, cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
- Strauss D. J., Gaynor J. J., Myers J. Prognostic Factors among 185 adult with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross-resistant chemotherapy and intermediate-dose radiation therapy. J. Clin. Oncol 1990; 7: 1173–1176
- Bradley S. J., Pearce R., Taghipour G. First remission autologous bone marrow transplantation for Hodgkin' s disease, preliminary EBMT data. Leukemia and Lymphoma 1995; 15: 51–53, Suppl. 1
- Sureda A., Burnet S., Lopez J. J. High-dose chemotherapy with bone marrow rescue for treatment of Hodgkin's Disease. Leukemia & Lymphoma 1992; 7: 29–31, (Suppl.)
- Moreau P., Milpied N., Mechinaud-Lacroix F. Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. Leukemia & Lymphoma 1993; 12: 51–58
- Federico M., Clò V., Carella A. M. Preliminary analysis of clinical characteristics of patients enrolled in the HD01 Protocol: A randomised trial of High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's disease responding to first line therapy. Leukemia and Lymphoma 1995; 15: 63–66, Suppl. 1